Colorectal cancer with peritoneal metastases
Conditions
Brief summary
Objective response rates according to radiological PCI after 3 cycles of treatment.
Detailed description
• Conversion rate to CRS+HIPEC as determined at the second MDT. • Safety as defined by AER from date of randomization until 3 weeks after last treatment cycle. • Overall survival during 3.5 year follow-up • Progression-free survival defined as documented disease progression or death from any cause during 3.5 year follow-up • Patient-derived scaffolding and FMCA analysis will evaluate chemotherapy sensitivity and its predictive value for response rates.
Interventions
DRUGlösning
DRUGlösning.
DRUGMitomycin Substipharm 20 mg
DRUGpulver till injektions-/infusionsvätska
DRUGlösning eller för intravesikal användning
DRUGIrinotecan Accord 20 mg/ml koncentrat till infusionsvätska
Sponsors
Uppsala University Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rates according to radiological PCI after 3 cycles of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| • Conversion rate to CRS+HIPEC as determined at the second MDT. • Safety as defined by AER from date of randomization until 3 weeks after last treatment cycle. • Overall survival during 3.5 year follow-up • Progression-free survival defined as documented disease progression or death from any cause during 3.5 year follow-up • Patient-derived scaffolding and FMCA analysis will evaluate chemotherapy sensitivity and its predictive value for response rates. | — |
Outcome results
None listed